Investor Relations

Corporate Overview

Myriad Genetics is a leading molecular diagnostic company dedicated to developing and marketing transformative tests which assess a person’s risk of developing disease, guide treatment decisions and help improve the quality of patient’s lives. Myriad’s portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual’s decision making process for monitoring and treating disease.

News Releases

Jan 18, 2012
Myriad Genetics Acquires Exclusive Rights to RAD51C Gene

Jan 17, 2012
Myriad Genetics to Announce Fiscal 2012 Second Quarter Results on Tuesday, January 31, 2012

View all releases »

Events & Presentations

Myriad Corporate Presentation

Upcoming Event
Jan 31, 2012 4:30 PM ET	Myriad Genetics Second Quarter Fiscal 2012 Financial Results Conference Call Listen to webcast Remind me Please sign up for email alert notification.

View all events & presentations »